A new type 2 diabetes treatment has been approved by the Food and Drug Administration (FDA). Jentadeuto, made by Eli Lily & Co., combines the longtime treatment metformin hydrochloride with linagliptin, known by the brand name Tradjenta, which was approved by the FDA in May. The new medication is designed to be used along with diet and exercise to help control blood sugar.
The FDA approved Jentadeuto to be used alone or in combination with sulfonylurea, another medication used to treat type 2 diabetes.
Type 2 diabetes medications have come under close review not only in the United States but worldwide. Last year the FDA put the drug Avandia under severe restrictions based on data from a study that linked the type 2 diabetes treatment to fatal heart attacks.
A few months later, the FDA issued a warning about Actos, another type 2 diabetes drug, after studies showed the drug put users at risk for bladder cancer. The risk was more defined in patients who used the drug long term.
The FDA regularly monitors adverse and allergic reactions with drugs approved for use and marketed in the United States. Any side effects with Jentadeuto or any other medication should be reported to the FDA MedWatch Adverse Event Reporting Program at www.FDA.gov/MedWatch/gotforms.htm.
ACTOS, ACTOplus met, ACTOplus met XR, and duetact are trademarks of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.
AVANDIA is a registered trademark of GlaxoSmithKline.